| 形态 | Liquid |
|---|
| 宿主种属 | Human |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | IgG4-lambda |
|---|
| 纯度 | >95% as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 1 mg/ml |
|---|
| 内毒素水平 | Please contact with the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | IL13, NC30, Interleukin-13, IL-13 |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | P35225 |
|---|
| 背景信息 | Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
|
|---|
| 别名 | CAT-354, 1044515-88-9 |
|---|
| 种属 | Human |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|